OVID

Ovid Therapeutics Inc. (OVID) | Rumor.io

Ovid Therapeutics

OVID

Attention (50-day avg)0%

Attention rank (50-day avg)#2,281

Bullish sentiment (50-day avg)100%

Price to earnings ratio-10.7

Market capitalization480.4M

Earnings per share-0.22

Dividend yield (TTM)—

Revenue (annual)7.3M

Net income (annual)-17.4M

Social

What share of all stock conversation is about OVID?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Mar 20

Ovid Therapeutics Inc. (OVID) price target raised to $7 from $5 by Wedbush analyst Laura Chico, maintaining an Outperform rating.
The company's Q4 update included a $60M private placement, 7mg OV329 data, and expansion of the OV329 program, highlighting its momentum.
OVID is considered an institutionally backed momentum biotech with a compressed biotech range, potentially leading to significant upside.

Generated by AI

Sentiment

Of the messages about OVID that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.04% -4.54
Bearish	—	—	—	10.96% +4.54

Bullish· Mar 18

$OVID has a strong base for a bounce back to pre-market runs, with a nice balance of volume and price action.
The company is seeing repeat attention, indicating traders are positioning for updates, which can lead to a quick price move on confirmation.
$OVID has a high potential for growth, with positive news and a great price entry point, making it a good investment opportunity.

Bearish· Oct 3

The company's warrants and financing deals are a major concern, leading to dilution and a downtrend in the stock price.
The stock is experiencing heavy resistance at its current price, with many traders expecting it to continue downward and potentially drop below $1.
The company's recent news and announcements have been met with skepticism, with some traders accusing the company of being involved in a pump and dump scheme.

Generated by AI

Topics

Of the messages about OVID that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	64.86%	82.72%
Analysts	—	100%	35.14%	7.43%
Earnings	—	0%	0%	2.48%
Controversies	—	0%	0%	0.8%
Macro	—	0%	0%	1.24%
Technical Analysis	—	0%	0%	5.33%

Analysts· Jun 18

Analysts at Cantor Fitzgerald maintain an Overweight rating for Ovid Therapeutics, raising the price target from $7 to $13.
Analysts at LADENBURG THALM/SH SH reiterate a "Buy" rating for Ovid Therapeutics, with a price target of $20.
Analysts at Piper Sandler reiterate an Overweight rating for Ovid Therapeutics, with a price target of $10.

Announcements· Oct 3

Ovid Therapeutics Inc. (OVID) announced the pricing of a private placement totaling up to $175 million in gross proceeds.
The initial closing of approximately $81 million is expected to fund the company's current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants.
OVID's next-generation GABA-aminotransferase inhibitor, OV329, demonstrated positive topline results, showing strong inhibitory activity and a potentially best-in-category safety profile.

Technical Analysis· Mar 3

Ovid Therapeutics Inc. ($OVID) is showing a G/C pattern with a potential gap continuation, making it a short sellers' paradise.
The stock has a key break point at $6.13, which is the bottom of a green cloud, and has the potential to run with a clear buy signal.
The chart indicates a range of $5.15 to $6.05 for the day, with a strong 4.2 support level, but the direction is uncertain due to lack of volume.

Generated by AI

Community

Of the messages about OVID, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	80.3%	61.42%
Newcomers	—	100%	19.7%	38.58%

Regulars· Oct 3

Ovid Therapeutics Inc. has announced positive topline results for its next-generation GABA-aminotransferase inhibitor, OV329, which demonstrate strong inhibitory activity and a potential best-in-category safety profile.
The company has also announced a private placement of up to $175 million in gross proceeds, which will be used to advance its clinical programs.
Ovid Therapeutics' Phase 1 study of OV329 has shown favorable safety results, with no eye issues reported, and the company is advancing to Phase 2a, with initiation planned for Q2 2026 and completion in mid-2027.

Newcomers· Oct 3

Ovid Therapeutics Inc. (OVID) has announced the pricing of a private placement totaling up to $175 million in gross proceeds, with an initial closing of approximately $81 million expected to fund its current operating plan and clinical pipeline into 2028.
The company's stock has experienced a significant increase in price, with a 28% jump after the announcement, and is now compressing into a descending triangle near $1.85, with volume still elevated.
OVID's recent data release has been well-received, with its lead asset OV329 showing strong GABA-AT inhibition and no evidence of ophthalmic or retinal changes observed, making it an attractive stock for traders with a potential price target of $3.00.

Generated by AI

On August 13, Ovid Therapeutics (NASDAQ:OVID) reported financial results for the second quarter ended June 30, alongside a batch of pipeline updates. The biopharmaceutical company, which focuses on treatments for brain disorders, used the update to lay out progress on two clinical programs, a leadership shakeup, and a deal that hands off one of its […]

18d agoYahoo! Finance Canada

H.C. Wainwright raises Ovid Therapeutics price target to $5 on pipeline progress

18d agoInvesting.com

Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus

20d agoInvesting.com

Ovid Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company’s management will participate in two upcoming investor conferences: Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ETH.C. Wainwright 28th Annual Global Investment Conference – Monday, September 14 at 11:30 am ET Webcasts of the pre

26d agoYahoo Finance

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?

Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.

1mo agoYahoo Finance

Also Discussed

Investors talking about OVID also mention

#	Name	Attention
1	CytomX Therapeutics, Inc.CTMX	0%0
2	KORU Medical Systems Inc.KRMD	0%0
3	Aprea Therapeutics, Inc.APRE	0%0
4	Solid Biosciences Inc.SLDB	0.3%new
5	ALRN - Aileron Therapeutics, Inc.	——
6	PMV Pharmaceuticals, Inc.PMVP	0%0
7	NextCure, Inc.NXTC	0%0
8	Repay Holdings Corporation Class A Common StockRPAY	0%0
9	Assembly Biosciences Inc.ASMB	0%new
10	Galapagos NV American Depositary ReceiptGLPG	0%0

Ovid Therapeutics Inc.

Healthcare
Biotechnology

Ovid Therapeutics Inc. is a biopharmaceutical company focused on developing small molecule medicines for brain disorders, with an emphasis on epilepsies and other seizure-related neurological conditions. The company’s current pipeline centers on therapies designed to address significant unmet needs in central nervous system diseases, including OV329, a GABA-AT inhibitor in clinical development, and OV4071, an oral KCC2 activator being studied for select neuropsychiatric and neurological indications. Ovid Therapeutics works at the intersection of drug discovery and clinical development, advancing mechanism-based programs aimed at rare and complex disorders where treatment options remain limited. Its role in the market is to identify differentiated candidates for neurological and neuropsychiatric diseases and progress them through early-stage testing toward potential therapeutic use.

Website

Location

Hudson Commons

New York, NY, 10001

United States

Social

What share of all stock conversation is about OVID?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Mar 20

Ovid Therapeutics Inc. (OVID) price target raised to $7 from $5 by Wedbush analyst Laura Chico, maintaining an Outperform rating.
The company's Q4 update included a $60M private placement, 7mg OV329 data, and expansion of the OV329 program, highlighting its momentum.
OVID is considered an institutionally backed momentum biotech with a compressed biotech range, potentially leading to significant upside.

Generated by AI

Sentiment

Of the messages about OVID that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	89.04% -4.54
Bearish	—	—	—	10.96% +4.54

Bullish· Mar 18

$OVID has a strong base for a bounce back to pre-market runs, with a nice balance of volume and price action.
The company is seeing repeat attention, indicating traders are positioning for updates, which can lead to a quick price move on confirmation.
$OVID has a high potential for growth, with positive news and a great price entry point, making it a good investment opportunity.

Bearish· Oct 3

The company's warrants and financing deals are a major concern, leading to dilution and a downtrend in the stock price.
The stock is experiencing heavy resistance at its current price, with many traders expecting it to continue downward and potentially drop below $1.
The company's recent news and announcements have been met with skepticism, with some traders accusing the company of being involved in a pump and dump scheme.

Generated by AI

Topics

Of the messages about OVID that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	64.86%	82.72%
Analysts	—	100%	35.14%	7.43%
Earnings	—	0%	0%	2.48%
Controversies	—	0%	0%	0.8%
Macro	—	0%	0%	1.24%
Technical Analysis	—	0%	0%	5.33%

Analysts· Jun 18

Analysts at Cantor Fitzgerald maintain an Overweight rating for Ovid Therapeutics, raising the price target from $7 to $13.
Analysts at LADENBURG THALM/SH SH reiterate a "Buy" rating for Ovid Therapeutics, with a price target of $20.
Analysts at Piper Sandler reiterate an Overweight rating for Ovid Therapeutics, with a price target of $10.

Announcements· Oct 3

Ovid Therapeutics Inc. (OVID) announced the pricing of a private placement totaling up to $175 million in gross proceeds.
The initial closing of approximately $81 million is expected to fund the company's current operating plan and clinical pipeline into 2028, with potential for up to $94 million in additional proceeds upon exercise of issued warrants.
OVID's next-generation GABA-aminotransferase inhibitor, OV329, demonstrated positive topline results, showing strong inhibitory activity and a potentially best-in-category safety profile.

Technical Analysis· Mar 3

Ovid Therapeutics Inc. ($OVID) is showing a G/C pattern with a potential gap continuation, making it a short sellers' paradise.
The stock has a key break point at $6.13, which is the bottom of a green cloud, and has the potential to run with a clear buy signal.
The chart indicates a range of $5.15 to $6.05 for the day, with a strong 4.2 support level, but the direction is uncertain due to lack of volume.

Generated by AI

Community

Of the messages about OVID, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	0%	80.3%	61.42%
Newcomers	—	100%	19.7%	38.58%

Regulars· Oct 3

Ovid Therapeutics Inc. has announced positive topline results for its next-generation GABA-aminotransferase inhibitor, OV329, which demonstrate strong inhibitory activity and a potential best-in-category safety profile.
The company has also announced a private placement of up to $175 million in gross proceeds, which will be used to advance its clinical programs.
Ovid Therapeutics' Phase 1 study of OV329 has shown favorable safety results, with no eye issues reported, and the company is advancing to Phase 2a, with initiation planned for Q2 2026 and completion in mid-2027.

Newcomers· Oct 3

Ovid Therapeutics Inc. (OVID) has announced the pricing of a private placement totaling up to $175 million in gross proceeds, with an initial closing of approximately $81 million expected to fund its current operating plan and clinical pipeline into 2028.
The company's stock has experienced a significant increase in price, with a 28% jump after the announcement, and is now compressing into a descending triangle near $1.85, with volume still elevated.
OVID's recent data release has been well-received, with its lead asset OV329 showing strong GABA-AT inhibition and no evidence of ophthalmic or retinal changes observed, making it an attractive stock for traders with a potential price target of $3.00.

Generated by AI

Ovid Therapeutics

Social

Mar 20

Bullish· Mar 18

Bearish· Oct 3

Analysts· Jun 18

Announcements· Oct 3

Technical Analysis· Mar 3

Regulars· Oct 3

Newcomers· Oct 3

Ovid Therapeutics at H.C. Wainwright conference: pipeline bets gain focus

Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two

H.C. Wainwright raises Ovid Therapeutics price target to $5 on pipeline progress

Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus

Ovid Therapeutics to Participate in Upcoming Investor Conferences

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?

Also Discussed

Ovid Therapeutics Inc.

Company Information

Location

Ovid Therapeutics at H.C. Wainwright conference: pipeline bets gain focus

Ovid Therapeutics (OVID) Cashes In One Bet To Fund Its Next Two

H.C. Wainwright raises Ovid Therapeutics price target to $5 on pipeline progress

Ovid Therapeutics at cantor healthcare: kcc2 and epilepsy in focus

Ovid Therapeutics to Participate in Upcoming Investor Conferences

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?

Also Discussed

Social

Mar 20

Bullish· Mar 18

Bearish· Oct 3

Analysts· Jun 18

Announcements· Oct 3

Technical Analysis· Mar 3

Regulars· Oct 3

Newcomers· Oct 3